Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2008

View Archived Issues

Menveo meningococcal vaccine immunogenic in infants

Antidepressant-mGlu2/3 receptor agonist combination may improve depression

New glucocorticoid receptor agonists prepared and tested at GlaxoSmithKline

New antidiabetic agents described in recent patents

New anticancer agents disclosed in recent patent literature

Sarcosine monotherapy assessed in schizophrenia patients

Neurokinin 1 receptors linked to control of aggressiveness

Orphan drug status granted for Marshall Edwards' anticancer drug triphendiol

Anavex outlines milestones, pipeline progress and plans for 2008

EpiCept updates progress with Ceplene and EpiCept NP-1 Cream

Hadasit, Harvard and BWH collaborate for autoimmune disease

Oramed commences phase Ib oral insulin trial

Peregrine receives approval to conduct phase II bavituximab trials in lung and breast cancer

Protalix extends research agreement with Yissum based on promising AChE data

Tercica initiates phase II next-generation growth hormone trial

EntreMed commences phase II MKC-1 study in ovarian/endometrial cancers

Genaera's diabetes IND in effect for trodusquemine

Nventa finishes enrollment and initiates dosing in HspE7 cervical dysplasia trial

Vertex initiates phase III development of HCV protease inhibitor telaprevir

Progenics initiates phase II PRO-140 trial for HIV

Amoxicillin extended release tablets to be marketed as Moxatag

BTG presents pipeline update

Dosing begins for U.S. phase I study of Hematide in chemotherapy-induced anemia

EMEA issues positive opinion of Cephalon's Effentora in breakthrough cancer pain

EMEA positive opinion for Thalidomide Pharmion as first-line multiple myeloma therapy

Mochida launches Dinagest Tab. 1 mg in Japan for endometriosis indication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...